Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis

NARecruitingINTERVENTIONAL
Enrollment

52,500

Participants

Timeline

Start Date

August 21, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
SepsisSepsis MrsaSepsis BacteremiaAntimicrobial - Induced NephropathySepsis, SevereSeptic ShockSeptic Syndrome
Interventions
BEHAVIORAL

Multifaceted de-implementation strategy to reduce vancomycin overuse

"* Clinical guidelines and group-level feedback on vancomycin use will be provided to clinicians/sepsis stakeholders at each site.~* The semi-structured interviews will be performed by a trained member of the research team, under the supervision of a medical sociologist who is one of the co-investigators. A semi-structured interview guide will be used during the interviews. Interviews will be recorded and transcribed, then uploaded to a qualitative analysis software for management and coding. Names will not be recorded, and pseudonyms will be used in notes, communications about the study, and any presentations. Verbal consent will be obtained before conducting and recording the interviews.~* The surveys will be performed using REDCap survey software, and participation will be voluntary. No identifiers will be collected."

Trial Locations (4)

19146

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

21287

RECRUITING

Johns Hopkins Children's Center, Baltimore

30322

RECRUITING

Children's Healthcare of Atlanta, Atlanta

63110

RECRUITING

St. Louis Children's Hospital, St Louis

Sponsors
All Listed Sponsors
collaborator

Children's Healthcare of Atlanta

OTHER

collaborator

St. Louis Children's Hospital

OTHER

collaborator

Johns Hopkins University

OTHER

collaborator

University of Pennsylvania

OTHER

collaborator

Centers for Disease Control and Prevention

FED

lead

Children's Hospital of Philadelphia

OTHER

NCT05975671 - Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis | Biotech Hunter | Biotech Hunter